These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16287616)

  • 41. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
    Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
    Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
    Danzi GB; Capuano C; Sesana M; Baglini R
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):179-84. PubMed ID: 14755808
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
    Sudo T; Ito H; Ozeki Y; Kimura Y
    Br J Pharmacol; 2001 Aug; 133(8):1396-404. PubMed ID: 11498527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium.
    Falcon CR; Cattaneo M; Ghidoni A; Mannucci PM
    Thromb Haemost; 1993 Sep; 70(3):389-92. PubMed ID: 8259535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
    Saucedo JF; Garza L; Wolford DC; Cook SL; Ramanathan KB; Matin Z; McGrew FA; Jacoski MV; Jennings LK;
    Am J Cardiol; 2004 May; 93(10):1279-82. PubMed ID: 15135704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
    Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of platelet aggregometry in dogs using the Multiplate platelet analyzer: impact of anticoagulant choice and assay duration.
    Marschner CB; Kristensen AT; Spodsberg EH; Wiinberg B
    J Vet Emerg Crit Care (San Antonio); 2012 Feb; 22(1):107-15. PubMed ID: 23016746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.
    Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Lo MW; Yin KC; Aggarwal A; Kabbani SS; DiBattiste PM
    Am J Cardiol; 2003 Feb; 91(3):334-6. PubMed ID: 12565092
    [No Abstract]   [Full Text] [Related]  

  • 51. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Kırma C; Erkol A; Pala S; Oduncu V; Dündar C; İzgi A; Tigen K; Gibson CM
    Catheter Cardiovasc Interv; 2012 Jan; 79(1):59-67. PubMed ID: 21523892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
    Danzi GB; Sesana M; Capuano C; Mauri L; Berra Centurini P; Baglini R
    Am J Cardiol; 2004 Jul; 94(1):35-9. PubMed ID: 15219505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood.
    Tóth O; Calatzis A; Penz S; Losonczy H; Siess W
    Thromb Haemost; 2006 Dec; 96(6):781-8. PubMed ID: 17139373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin.
    Wallén NH; Ladjevardi M; Albert J; Bröijersén A
    Thromb Res; 1997 Jul; 87(1):151-7. PubMed ID: 9253810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ethanol enhances the inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet function.
    Rand ML; Jakubowski JA; Fisher MJ; Chahil A; Kinlough-Rathbone RL; Packham MA
    J Lab Clin Med; 2002 Dec; 140(6):391-7. PubMed ID: 12486406
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study.
    Li SW; Feng X; Xu H; Chen KJ
    Chin J Integr Med; 2018 Feb; 24(2):103-108. PubMed ID: 29067595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.